ADM Korea (187660) Stock Overview

ADM Korea Inc. provides clinical services in Asia. The company provides regulatory affairs services, including strategic and regulatory drug development consulting, preparation and document validation of registration dossier, IND and NDA application support, scientific and medical communication with regulatory authorities, and post-approval maintenance support; and clinical operation services, such as protocol and CRF development, investigator and site selection, feasibility study, dossier develop and translation, site qualification visit, site initiation visit, interim monitoring visit, close-out visit, site management, and CSR writing services. It also offers project management services comprising site management, vendor management, IP management, SAE management, and document management; quality assurance/audit services, such as contracted system audit, contracted site audit, contracted in-house audit, internal audit for cause and TMF audit, preparation and training for the inspection, and professional training for a clinical trial; and post marketing surveillance services, including protocol and CRF development, IRB submission, site contract, investigational staff training, project management, monitoring, safety report, and periodic and re-examination report writing. In addition, the company provides data management services consisting of data management plan development, customized database design and validation, double independent data entry and unmatched check, data validation and check report, data review listings for study whole data, SAE reconciliation, data quality reviews, electronic data transfer, and back-up and security, as well as medical coding, such as MedDRA, WHO ART, and WHO ATC; statistical analysis services, which include statistical consulting, statistical analysis plan, Web based randomization, and SAS software programming for result and output; and EDC solution services. ADM Korea Inc. was founded in 2003 and is based in Seoul, South Korea.